Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have been given a consensus recommendation of “Buy” by the eight ratings firms that are currently covering the firm, MarketBeat reports. Eight equities research analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $6.63.

A number of research analysts recently weighed in on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $6.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th.

Taysha Gene Therapies Trading Up 8.0 %

NASDAQ:TSHA opened at $3.24 on Friday. The company has a market cap of $664.01 million, a P/E ratio of 5.14 and a beta of 0.44. Taysha Gene Therapies has a twelve month low of $1.19 and a twelve month high of $4.32. The business has a 50 day moving average price of $2.06 and a two-hundred day moving average price of $2.39. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in the business. Creative Planning acquired a new position in shares of Taysha Gene Therapies during the 3rd quarter worth approximately $28,000. Principal Financial Group Inc. acquired a new position in shares of Taysha Gene Therapies in the second quarter valued at $48,000. China Universal Asset Management Co. Ltd. raised its position in shares of Taysha Gene Therapies by 79.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock valued at $79,000 after purchasing an additional 17,446 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Taysha Gene Therapies during the 3rd quarter worth about $85,000. Finally, Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth about $97,000. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.